Insmed Option Alert: May 16 $72.5 Puts at the Bid: 2971 vs 26 OI; Earnings 5/8 Before Open [est] 

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 2971 @ $4.4 vs 26 OI; Earnings 5/8 Before Open [est] Ref=$72.735

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 3964 vs 26 OI; Earnings 5/8 Before Open [est] 

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 3964 @ $4.4 vs 26 OI; Earnings 5/8 Before Open [est] Ref=$73.34

Insmed

INSMED INC

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

chart investors ai

Broad U.S. Equity ETFs

Trading Ideas

ETFs

CRDO

FTAI

INSM

PCVX

RKLB

UFPI

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000&#39;s 15% drop. Some top stocks saw even bigger declines.

Are Small-Cap Stocks A Buy After Russell 2000 Correction?

GraniteShares 2x Long META Daily ETF (FBL)

New ETFs

FTAIM

First Trust Exchange-Traded Fund VI First Trust Small Cap BuyWrite Income ETF

FTKI

First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%.

First Trust&#39;s New Small-Cap ETF Aims To Combine Growth With Income

Insmed’s Stellar Performance Draws Attention

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

General

RBC Capital initiates Insmed with an Outperform rating, citing brensocatib&#39;s launch potential and Arikayce&#39;s growth. FDA decision on brensocatib due August 2025.

Lung Disease-Focused Insmed &#39;Is An Attractive Midcap Biotech,&#39; Analyst Says

Insmed Inc

Press Releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed To Present at March 2025 Investor Conferences

Earnings

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:46 PMApr 01, 2025	PUT	$72.50	May 16, 2025	39	4033	2971	15512	26	TRADE	BULLISH
02:38 PMApr 01, 2025	PUT	$72.50	May 16, 2025	39	5025	3964	19327	26	TRADE	NEUTRAL

Comments

Insmed

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga